Add this topic to your myFT Digest for news straight to your inbox
With a bidding war for Allergan, who the buyer is matters less than the size of the premium
The Actavis buy more than doubles its global presence but big deals cannot offset generic pharma’s problems
Strategy could be model for pharmaceuticals
S&P 500 has best day since August
Drug accounts for about 20% of US sales
International Edition